{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:11:28Z","timestamp":1779192688413,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA237243"],"award-info":[{"award-number":["R01CA237243"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA248158-01"],"award-info":[{"award-number":["R01CA248158-01"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01 AG069727-01"],"award-info":[{"award-number":["R01 AG069727-01"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA284630"],"award-info":[{"award-number":["1R01CA284630"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CSCC-Team-23-978452-01-CSCC"],"award-info":[{"award-number":["CSCC-Team-23-978452-01-CSCC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["NXTGN-25-004"],"award-info":[{"award-number":["NXTGN-25-004"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer and Black American (BA) women face disproportionately higher mortality rates than White American (WA) women. The molecular mechanism behind this disparate clinical outcome remains poorly understood. We find that BA TNBC patients exhibit higher protein expression of KRT17 compared to WA TNBC and non-TNBC patients and correlates to poor distant metastasis-free survival. Mechanistic studies in metastatic mouse TNBC tumors with higher Krt17 demonstrates higher Wnt signaling targets, cancer stem cells (CSCs), which positively correlates to several metastasis signatures, supporting clinical data. Consistently, KRT17\n                    <jats:sup>high<\/jats:sup>\n                    BA patient tumors display higher activated Wnt signaling. Furthermore, Krt17 regulates Wnt signaling to drive recruitment of \u03b3\u03b4 T-cells in both mouse and human samples, which can be reversed by targeting Wnt signaling, identifying the Krt17-Wnt signaling axis as a critical driver of clinical disparities and a novel targetable vulnerability for BA TNBC patients.\n                  <\/jats:p>","DOI":"10.1038\/s42003-026-09897-0","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:00:24Z","timestamp":1774544424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRT17 promotes triple negative breast cancer through activation of Wnt signaling and \u03b3\u03b4 T-cells recruitment"],"prefix":"10.1038","volume":"9","author":[{"given":"Chermakani","family":"Panneer Selvam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-4442","authenticated-orcid":false,"given":"Gatha","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youley","family":"Tjendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda M.","family":"Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila O.","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7720-9660","authenticated-orcid":false,"given":"Rumela","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"9897_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15, 121 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"9897_CR2","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11, e0157368 (2016).","journal-title":"PLoS ONE"},{"key":"9897_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y-Z Jiang","year":"2019","unstructured":"Jiang, Y.-Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35, 428\u2013440.e425 (2019).","journal-title":"Cancer Cell"},{"key":"9897_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. npj Breast Cancer 8, 95 (2022).","journal-title":"npj Breast Cancer"},{"key":"9897_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J.-J., Bian, X.-W. & Yu, S. -c Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 1\u201313 (2020).","journal-title":"Breast Cancer Res."},{"key":"9897_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.576964","volume":"8","author":"O Prakash","year":"2020","unstructured":"Prakash, O. et al. Racial disparities in triple negative breast cancer: a review of the role of biologic and non-biologic factors. Front. Public Health 8, 576964 (2020).","journal-title":"Front. Public Health"},{"key":"9897_CR7","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/S1470-2045(14)70364-X","volume":"15","author":"AM Brewster","year":"2014","unstructured":"Brewster, A. M., Chavez-MacGregor, M. & Brown, P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.  Lancet Oncol. 15, e625\u2013e634 (2014).","journal-title":"Lancet Oncol."},{"key":"9897_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1055-9965.EPI-15-0243","volume":"24","author":"L Tao","year":"2015","unstructured":"Tao, L., Gomez, S. L., Keegan, T. H., Kurian, A. W. & Clarke, C. A. Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol. Biomark. Prev. 24, 1039\u20131045 (2015).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"9897_CR9","unstructured":"Alonso, A., Ikinger, U. & Kartenbeck, J. Staining patterns of keratins in the human urinary tract. Histol. Histopathol. 24, 1425\u201337 (2009)."},{"key":"9897_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1242\/jcs.93.3.419","volume":"93","author":"S Troyanovsky","year":"1989","unstructured":"Troyanovsky, S., Guelstein, V., Tchipysheva, T., Krutovskikh, V. & Bannikov, G. Patterns of expression of keratin 17 in human epithelia: dependency on cell position. J. Cell Sci. 93, 419\u2013426 (1989).","journal-title":"J. Cell Sci."},{"key":"9897_CR11","first-page":"127","volume":"59","author":"SM Troyanovsky","year":"1992","unstructured":"Troyanovsky, S. M., Leube, R. E. & Franke, W. W. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur. J. Cell Biol. 59, 127\u2013137 (1992).","journal-title":"Eur. J. Cell Biol."},{"key":"9897_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1600-0625.2009.01006.x","volume":"20","author":"I Kurokawa","year":"2011","unstructured":"Kurokawa, I., Takahashi, K., Moll, I. & Moll, R. Expression of keratins in cutaneous epithelial tumors and related disorders\u2013distribution and clinical significance. Exp. Dermatol. 20, 217\u2013228 (2011).","journal-title":"Exp. Dermatol."},{"key":"9897_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13258-023-01437-y","volume":"45","author":"L Wu","year":"2023","unstructured":"Wu, L., Ding, W., Wang, X., Li, X. & Yang, J. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt\/beta-catenin signaling pathway. Genes Genom. 45, 1329\u20131338 (2023).","journal-title":"Genes Genom."},{"key":"9897_CR14","doi-asserted-by":"publisher","first-page":"818416","DOI":"10.3389\/fcell.2022.818416","volume":"10","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. The role of keratin17 in human tumours. Front. Cell Dev. Biol. 10, 818416 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"9897_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1083\/jcb.132.3.381","volume":"132","author":"P Rd","year":"1996","unstructured":"Rd, P. Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16. J. Cell Biol. 132, 381\u2013397 (1996).","journal-title":"J. Cell Biol."},{"key":"9897_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ced.13227","volume":"43","author":"A Moy","year":"2018","unstructured":"Moy, A., Murali, M., Kroshinsky, D., Horn, T. & Nazarian, R. T-helper immune phenotype may underlie \u2018paradoxical\u2019tumour necrosis factor-\u03b1 inhibitor therapy-related psoriasiform dermatitis. Clin. Exp. Dermatol. 43, 19\u201326 (2018).","journal-title":"Clin. Exp. Dermatol."},{"key":"9897_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jdermsci.2012.06.008","volume":"67","author":"M Fu","year":"2012","unstructured":"Fu, M. & Wang, G. Keratin 17 as a therapeutic target for the treatment of psoriasis. J. Dermatol. Sci. 67, 161\u2013165 (2012).","journal-title":"J. Dermatol. Sci."},{"key":"9897_CR18","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1158\/1078-0432.CCR-21-3039","volume":"28","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Stress keratin 17 expression in head and neck cancer contributes to immune evasion and resistance to immune-checkpoint blockade. Clin. Cancer Res. 28, 2953\u20132968 (2022).","journal-title":"Clin. Cancer Res."},{"key":"9897_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/PAI.0000000000000862","volume":"29","author":"K Haye","year":"2021","unstructured":"Haye, K. et al. Keratin 17 expression predicts poor clinical outcome in patients with advanced esophageal squamous cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 29, 144\u2013151 (2021).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"9897_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s13277-013-0703-5","volume":"34","author":"Y-F Wang","year":"2013","unstructured":"Wang, Y.-F. et al. Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumor Biol. 34, 1685\u20131689 (2013).","journal-title":"Tumor Biol."},{"key":"9897_CR21","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-15-0293","volume":"75","author":"LF Escobar-Hoyos","year":"2015","unstructured":"Escobar-Hoyos, L. F. et al. Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res. 75, 3650\u20133662 (2015).","journal-title":"Cancer Res."},{"key":"9897_CR22","first-page":"6176043","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang, J., Lan, L., Ma, B., Ren, G. & Yin, C. KRT17 accelerates cell proliferative and invasive potential of laryngeal squamous cell carcinoma (LSCC) through regulating AKT\/mTOR and Wnt\/\u03b2-Catenin pathways. Evid. Based Complement. Altern. Med. 2022, 6176043 (2022).","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"9897_CR23","doi-asserted-by":"crossref","unstructured":"Slepicka, P. F., Somasundara, A. V. H. & Dos Santos, C. O. The molecular basis of mammary gland development and epithelial differentiation. Semin. Cell Dev. Biol. 114, 93\u2013112 (2021).","DOI":"10.1016\/j.semcdb.2020.09.014"},{"key":"9897_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu, X., Zhang, M., Xu, F. & Jiang, S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol. Cancer 19, 165 (2020).","journal-title":"Mol. Cancer"},{"key":"9897_CR25","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1038\/oncsis.2017.14","volume":"6","author":"S-G Pohl","year":"2017","unstructured":"Pohl, S.-G. et al. Wnt signaling in triple-negative breast cancer. Oncogenesis 6, e310\u2013e310 (2017).","journal-title":"Oncogenesis"},{"key":"9897_CR26","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1073\/pnas.1303671110","volume":"110","author":"JL Green","year":"2013","unstructured":"Green, J. L. et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc. Natl. Acad. Sci. USA. 110, 6991\u20136996 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"9897_CR27","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s11481-012-9367-y","volume":"7","author":"J Ma","year":"2012","unstructured":"Ma, J., Wang, R., Fang, X. & Sun, Z. -catenin\/TCF-1 pathway in T cell development and differentiation. J. Neuroimmune Pharmacol. 7, 750\u2013762 (2012).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"9897_CR28","doi-asserted-by":"crossref","unstructured":"Sung, B.-Y. et al. Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1. J. Clin. Investig. 132, e140508 (2022).","DOI":"10.1172\/JCI140508"},{"key":"9897_CR29","doi-asserted-by":"publisher","unstructured":"Mammadli, M. et al. Wnt\/\u03b2-catenin regulates alloreactive T cells for the treatment of hematological malignancies. bioRxiv https:\/\/doi.org\/10.1101\/2021.04.12.439538 (2021).","DOI":"10.1101\/2021.04.12.439538"},{"key":"9897_CR30","first-page":"100625","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation 5, 100625 (2024).","journal-title":"Innovation"},{"key":"9897_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327 (2022).","journal-title":"Neoplasia"},{"key":"9897_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. S. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649\u2013658 (2017).","journal-title":"Neoplasia"},{"key":"9897_CR33","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Investig."},{"key":"9897_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/bjc.2016.283","volume":"115","author":"G Houvenaeghel","year":"2016","unstructured":"Houvenaeghel, G. et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. Br. J. Cancer 115, 1024\u20131031 (2016).","journal-title":"Br. J. Cancer"},{"key":"9897_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4414","volume":"15","author":"G Thacker","year":"2023","unstructured":"Thacker, G. et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci. Transl. Med. 15, eabl4414 (2023).","journal-title":"Sci. Transl. Med."},{"key":"9897_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41556-020-0495-y","volume":"22","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. Loss of ELF5\u2013FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling. Nat. Cell Biol. 22, 591\u2013602 (2020).","journal-title":"Nat. Cell Biol."},{"key":"9897_CR37","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-15-0248","volume":"75","author":"H Katayama","year":"2015","unstructured":"Katayama, H. et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis. Cancer Res. 75, 3246\u20133254 (2015).","journal-title":"Cancer Res."},{"key":"9897_CR38","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA. 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"9897_CR39","doi-asserted-by":"crossref","unstructured":"Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 39, 20.2.1\u201320.2.16 (2000).","DOI":"10.1002\/0471142735.im2002s39"},{"key":"9897_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","volume":"10","author":"B Schr\u00f6rs","year":"2020","unstructured":"Schr\u00f6rs, B. et al. Multi-omics characterization of the 4T1 murine mammary gland tumor model. Front. Oncol. 10, 1195 (2020).","journal-title":"Front. Oncol."},{"key":"9897_CR41","doi-asserted-by":"crossref","unstructured":"Hua, Z., White, J. & Zhou, J. Cancer stem cells in TNBC. Semin. Cancer Biol. 82, 26\u201334 (2022).","DOI":"10.1016\/j.semcancer.2021.06.015"},{"key":"9897_CR42","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.3390\/cancers13246209","volume":"13","author":"L He","year":"2021","unstructured":"He, L., Wick, N., Germans, S. K. & Peng, Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers 13, 6209 (2021).","journal-title":"Cancers"},{"key":"9897_CR43","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/cam4.3295","volume":"9","author":"A Le Naour","year":"2020","unstructured":"Le Naour, A., Rossary, A. & Vasson, M. P. Eo771, is it a Well-Characterized cell line for mouse Mammary cancer model? limit and uncertainty. Cancer Med. 9, 8074\u20138085 (2020).","journal-title":"Cancer Med."},{"key":"9897_CR44","doi-asserted-by":"publisher","first-page":"e0155262","DOI":"10.1371\/journal.pone.0155262","volume":"11","author":"O Aprelikova","year":"2016","unstructured":"Aprelikova, O. et al. Development and preclinical application of an immunocompetent transplant model of basal breast cancer with lung, liver and brain metastases. PLoS ONE 11, e0155262 (2016).","journal-title":"PLoS ONE"},{"key":"9897_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02107-3","volume":"21","author":"P Merikhian","year":"2021","unstructured":"Merikhian, P., Eisavand, M. R. & Farahmand, L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell Int. 21, 419 (2021).","journal-title":"Cancer Cell Int."},{"key":"9897_CR46","doi-asserted-by":"publisher","first-page":"e9370","DOI":"10.1371\/journal.pone.0009370","volume":"5","author":"C Fuerer","year":"2010","unstructured":"Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS ONE 5, e9370 (2010).","journal-title":"PLoS ONE"},{"key":"9897_CR47","first-page":"1","volume":"16","author":"Zhao","year":"2018","unstructured":"Zhao, Niu, Y. & Cui, C. J. Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development? J. Transl. Med. 16, 1\u201313 (2018).","journal-title":"J. Transl. Med."},{"key":"9897_CR48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. \u03b3\u03b4 T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"9897_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.816005","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu, Z. et al. CD3+ CD4-CD8-(Double-negative) T cells in inflammation, immune disorders and cancer. Front. Immunol. 13, 816005 (2022).","journal-title":"Front. Immunol."},{"key":"9897_CR50","doi-asserted-by":"publisher","first-page":"20224","DOI":"10.1073\/pnas.1314239110","volume":"110","author":"J Liu","year":"2013","unstructured":"Liu, J. et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA. 110, 20224\u201320229 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"9897_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","volume":"125","author":"J Rodon","year":"2021","unstructured":"Rodon, J. et al. Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br. J. Cancer 125, 28\u201337 (2021).","journal-title":"Br. J. Cancer"},{"key":"9897_CR52","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ncb3040","volume":"16","author":"R Chakrabarti","year":"2014","unstructured":"Chakrabarti, R. et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 16, 1004\u20131015 (2014).","journal-title":"Nat. Cell Biol."},{"key":"9897_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1083\/jcb.200611114","volume":"177","author":"R Villadsen","year":"2007","unstructured":"Villadsen, R. et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 177, 87\u2013101 (2007).","journal-title":"J. Cell Biol."},{"key":"9897_CR54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10555-017-9725-6","volume":"37","author":"W Hankey","year":"2018","unstructured":"Hankey, W., Frankel, W. L. & Groden, J. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev. 37, 159\u2013172 (2018).","journal-title":"Cancer Metastasis Rev."},{"key":"9897_CR55","first-page":"76","volume":"44","author":"L Xu","year":"2023","unstructured":"Xu, L. et al. KRT17 promotes endometrial cancer cell migration as well as angiogenesis by regulating HIF-1\u03b1\/VEGF pathway. Eur. J. Gynaecol. Oncol. 44, 76\u201382 (2023).","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"9897_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2019.103557","volume":"211","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J. Proteom. 211, 103557 (2020).","journal-title":"J. Proteom."},{"key":"9897_CR57","doi-asserted-by":"publisher","first-page":"12598","DOI":"10.1080\/21655979.2021.2010393","volume":"12","author":"R Ji","year":"2021","unstructured":"Ji, R. et al. Keratin 17 upregulation promotes cell metastasis and angiogenesis in colon adenocarcinoma. Bioengineered 12, 12598\u201312611 (2021).","journal-title":"Bioengineered"},{"key":"9897_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00824-z","volume":"29","author":"T-H Jang","year":"2022","unstructured":"Jang, T.-H. et al. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin\/FAK\/Src\/ERK\/\u03b2-catenin pathway. J. Biomed. Sci. 29, 42 (2022).","journal-title":"J. Biomed. Sci."},{"key":"9897_CR59","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.18632\/oncotarget.2030","volume":"5","author":"R Chen","year":"2014","unstructured":"Chen, R. et al. Rac1 regulates skin tumors by regulation of keratin 17 through recruitment and interaction with CD11b+ Gr1+ cells. Oncotarget 5, 4406 (2014).","journal-title":"Oncotarget"},{"key":"9897_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/cells8080807","volume":"8","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Yin, M. & Zhang, L. -j Keratin 6, 16 and 17\u2014critical barrier alarmin molecules in skin wounds and psoriasis. Cells 8, 807 (2019).","journal-title":"Cells"},{"key":"9897_CR61","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201911053","volume":"219","author":"J Bajaj","year":"2019","unstructured":"Bajaj, J., Diaz, E. & Reya, T. Stem cells in cancer initiation and progression. J. Cell Biol. 219, e201911053 (2019).","journal-title":"J. Cell Biol."},{"key":"9897_CR62","first-page":"771","volume":"24","author":"JE Martens","year":"2004","unstructured":"Martens, J. E., Arends, J., Van Der Linden, P. J., De Boer, B. A. & Helmerhorst, T. J. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. Anticancer Res. 24, 771\u2013776 (2004).","journal-title":"Anticancer Res."},{"key":"9897_CR63","doi-asserted-by":"publisher","first-page":"31943","DOI":"10.18632\/oncotarget.8218","volume":"7","author":"E Ortiz-S\u00e1nchez","year":"2016","unstructured":"Ortiz-S\u00e1nchez, E. et al. Characterization of cervical cancer stem cell-like cells: phenotyping, stemness, and human papilloma virus co-receptor expression. Oncotarget 7, 31943 (2016).","journal-title":"Oncotarget"},{"key":"9897_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40778-016-0068-y","volume":"2","author":"D Bhavanasi","year":"2016","unstructured":"Bhavanasi, D. & Klein, P. S. Wnt signaling in normal and malignant stem cells. Curr. Stem Cell Rep. 2, 379\u2013387 (2016).","journal-title":"Curr. Stem Cell Rep."},{"key":"9897_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cancers8070065","volume":"8","author":"QC Yu","year":"2016","unstructured":"Yu, Q. C., Verheyen, E. M. & Zeng, Y. A. Mammary development and breast cancer: a Wnt perspective. Cancers 8, 65 (2016).","journal-title":"Cancers"},{"key":"9897_CR66","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30, R921\u2013R925 (2020).","journal-title":"Curr. Biol."},{"key":"9897_CR67","doi-asserted-by":"publisher","first-page":"e14283","DOI":"10.15252\/emmm.202114283","volume":"14","author":"Z Baumann","year":"2022","unstructured":"Baumann, Z. & Auf der Maur, P. & Bentires-Alj, M. Feed-forward loops between metastatic cancer cells and their microenvironment\u2014the stage of escalation. EMBO Mol. Med. 14, e14283 (2022).","journal-title":"EMBO Mol. Med."},{"key":"9897_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf, K. et al. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front. Immunol. 12, 656364 (2021).","journal-title":"Front. Immunol."},{"key":"9897_CR69","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"9897_CR70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"9897_CR71","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41416-020-0916-5","volume":"123","author":"R Plummer","year":"2020","unstructured":"Plummer, R. et al. First-in-human study of the PARP\/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. Br. J. Cancer 123, 525\u2013533 (2020).","journal-title":"Br. J. Cancer"},{"key":"9897_CR72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0192623315621192","volume":"44","author":"Y Zhong","year":"2016","unstructured":"Zhong, Y. et al. Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1. Toxicol. Pathol. 44, 267\u2013278 (2016).","journal-title":"Toxicol. Pathol."},{"key":"9897_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bone.2017.10.017","volume":"106","author":"S Fujita","year":"2018","unstructured":"Fujita, S. et al. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone 106, 156\u2013166 (2018).","journal-title":"Bone"},{"key":"9897_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond, J. R. et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res. Treat. 184, 53\u201362 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"9897_CR75","doi-asserted-by":"publisher","first-page":"e0117097","DOI":"10.1371\/journal.pone.0117097","volume":"10","author":"J Xu","year":"2015","unstructured":"Xu, J., Prosperi, J. R., Choudhury, N., Olopade, O. I. & Goss, K. H. \u03b2-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE 10, e0117097 (2015).","journal-title":"PLoS ONE"},{"key":"9897_CR76","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2353\/ajpath.2010.091125","volume":"176","author":"AI Khramtsov","year":"2010","unstructured":"Khramtsov, A. I. et al. Wnt\/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176, 2911\u20132920 (2010).","journal-title":"Am. J. Pathol."},{"key":"9897_CR77","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ncb3040","volume":"16","author":"R Chakrabarti","year":"2014","unstructured":"Chakrabarti, R. et al. \u0394Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 16, 1004\u20131015 (2014).","journal-title":"Nat. Cell Biol."},{"key":"9897_CR78","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386. e310 (2018).","journal-title":"Cell"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09897-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:02:45Z","timestamp":1779192165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09897-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9897"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09897-0","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}